Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26850422 | 0.91 | KCNH2 (0.34) | KDM4E | |
| SCHEMBL21719187 | 0.82 | KCNH2 (0.32) | KDM4E | |
| SCHEMBL18948756 | 0.76 | — | — | |
| SCHEMBL18948790 | 0.76 | — | — | |
| SCHEMBL803084 | 0.76 | SYK (0.39) | GRM4AAK1KDM4ELMNATSHR | |
| SCHEMBL18366965 | 0.74 | GRM4 (0.32) | NOS2GRM4AAK1KDM4ELMNA | |
| SCHEMBL18612886 | 0.74 | UHRF1 (0.42) | NOS2KDM4ELMNAARSREBF2 | |
| SCHEMBL18431417 | 0.73 | TLR8 (0.43) | — | |
| SCHEMBL20909663 | 0.72 | GRM4 (0.35) | GRM4AAK1KDM4ELMNA | |
| SCHEMBL28203328 | 0.72 | HCRTR1 (0.35) | GRM4AAK1KDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242319-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | NOS2 89/4885PDK2 1135/4885ESR1 3892/4885 |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | NOS2 89/4885PDK2 1135/4885ESR1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.